Researchers from The University of Texas MD Anderson Cancer Center have conducted the first randomized clinical trial comparing stereotactic radiosurgery (SRS) to whole brain radiation therapy (WBRT) in patients with four to 15 brain metastases, providing evidence to support the use of SRS in this patient population.
Results from the Phase III trial, led by Jing Li, M.D., Ph.D., associate professor of Radiation Oncology and co-director...
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov...
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused...
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed to address this devastating disease.
Earlier this year, The University of Texas MD Anderson Cancer Center, UT Austin Oden Institute for Computational Engineering and Sciences, and UT Austin Texas Advanced Computing Center (TACC) launched a new collaboration in Oncological Data and Computational...
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
The University of Texas MD Anderson Cancer Center today announced achievement of its fifth consecutive Magnet designation, the highest distinction...
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD...
Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19...
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...